Floatz logo

BMS-986345

Adult T-cell Leukemia/Lymphoma

National Cancer Institute (NCI)Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

8 Active assets in the Adult T-cell Leukemia/Lymphoma cohort.

Asset / SponsorPhaseRating
Azacitidine
National Cancer Institute (NCI)
Phase 2B
Ruxolitinib
Jonathan Brammer
Phase 2B
Venetoclax
The First Affiliated Hospital of Soochow University
Phase 2CCC
Tucidinostat
The First Affiliated Hospital of Soochow University
Phase 2CCC
VINDESINE
The First Affiliated Hospital of Soochow University
Phase 2CCC

View all 10 →

Same molecule, other indications

BMS-986345 is also rated in:

Chronic Lymphocytic LeukemiaDormant
B
Indicative ·
58 / 100
View asset →
Follicular LymphomaDormant
B
Indicative ·
56 / 100
View asset →
Indolent Non-Hodgkin LymphomaDormant
B
Indicative ·
56 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →